Opko Health Inc (OPK) : 4 analysts are covering Opko Health Inc (OPK) and their average rating on the stock is 2, which is read as a Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Opko Health Inc (OPK) : 3 Wall Street analysts covering Opko Health Inc (OPK) believe that the average level the stock could reach for the short term is $15.33. The maximum price target given is $20 and the minimum target for short term is around $10, hence the standard deviation is calculated at $5.03.
For the current week, the company shares have a recommendation consensus of Buy. Also, Deutsche Bank maintains their rating on the shares of Opko Health Inc (NYSE:OPK). The current rating of the shares is Hold. Equity Analysts at the Firm lowers the price target to $10 per share from $11 per share. The rating by the firm was issued on June 16, 2016.
Opko Health Inc (NYSE:OPK): The stock opened at $9.39 and touched an intraday high of $9.6 on Wednesday. During the day, the stock corrected to an intraday low of $9.38, however, the bulls stepped in and pushed the price higher to close in the green at $9.59 with a gain of 2.46% for the day. The total traded volume for the day was 2,632,994. The stock had closed at $9.36 in the previous trading session.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.